"Mannkind (MNKD): Mannkind is finally back over the two dollar mark after a late run last week. Shares closed higher by four percent on Friday on triple the average volume as investors absorbed clues that the company may take non-dilutive measures to raise cash later this year. Founder Al Mann already has a billion dollars invested in the company and may open the wallet again to keep dilution at a minimum.

Mannkind needs to complete additional trials for its inhaled insulin product, Afrezza, before having another go with the FDA. The trials are necessary because the company did not use the next-generation inhaler during the last round of Phase IIIs."

http://www.wallstreetwindow.com/aggregator/categories/1